AOD-9604
Metabolic / fat loss
Status & caution. Not FDA-approved (a food-ingredient pathway was explored but it is not an approved drug). Named in the 2026 reclassification discussion but NOT among the 12 peptides FDA advanced to PCAC review; sold grey-market as 'research only.' Marketed as 'fat loss without GH side effects,' but human efficacy trials were largely disappointing.
At a glance
Indications & what it's studied for
Promoted for fat metabolism/lipolysis without the IGF-1 rise of full GH; also explored for cartilage/osteoarthritis.
Contraindications & cautions
No established human contraindications; no approved drug use.
Commonly reported dosing
Reported, not recommended. The following describes what appears in research literature and community use. It is not a protocol, and unapproved peptides have no validated human dosing.
Community use reports small daily subcutaneous doses; efficacy is not well supported.
Routes of administration
Subcutaneous injection; oral forms marketed.
Don't combine with
No characterised interactions documented.
Reported to stack with
Sometimes combined with GH secretagogues for body-composition goals.
Note: "stacking" combines multiple agents and multiplies unknowns; popularity of a combination is not evidence of its safety.
What the research actually shows
Human obesity trials did not show meaningful weight loss versus placebo at tested doses, a key reason for scepticism.
Before acting on anything here, see Safety & the grey market and how to read a COA.